Neumora Therapeutics, Inc. Common Stock (NMRA) Stock
NASDAQ · NMRA
0.71
Fundamentals
Market cap
$127.32M
Price / Earnings ratio
-0.6x
Price / Sales ratio
N/A
Price / Book ratio
3.0x
Return on assets
-119.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
NeutralNMRAJune 18, 2026
Business WireNeutral
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
NMRA

Zacks Investment Research
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
NeutralNMRAJune 16, 2026
Zacks Investment ResearchNeutral
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
NMRA

Stocktwits
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials
NeutralNMRAJune 15, 2026
StocktwitsNeutral
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials
NMRA

Reuters
Neumora Therapeutics scraps depression drug after two late-stage trial failures
NeutralNMRAJune 15, 2026
ReutersNeutral
Neumora Therapeutics scraps depression drug after two late-stage trial failures
NMRA
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy1
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
NeutralNMRAJune 18, 2026
Business WireNeutral
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
NMRA

Zacks Investment Research
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
NeutralNMRAJune 16, 2026
Zacks Investment ResearchNeutral
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
NMRA

Stocktwits
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials
NeutralNMRAJune 15, 2026
StocktwitsNeutral
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials
NMRA

Reuters
Neumora Therapeutics scraps depression drug after two late-stage trial failures
NeutralNMRAJune 15, 2026
ReutersNeutral
Neumora Therapeutics scraps depression drug after two late-stage trial failures
NMRA

Business Wire
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
NeutralNMRAMarch 19, 2026
Business WireNeutral
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
NMRA

InvestorPlace
7 Stocks with Strong Insider Buying: December 2023
NeutralNMRADecember 17, 2023
InvestorPlaceNeutral
7 Stocks with Strong Insider Buying: December 2023
NMRA

Market Watch
IPO pipeline welcomes some profitable companies, raising hopes for a rebound
NeutralNMRANovember 20, 2023
Market WatchNeutral
IPO pipeline welcomes some profitable companies, raising hopes for a rebound
NMRA

InvestorPlace
Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO)
NeutralNMRASeptember 28, 2023
InvestorPlaceNeutral
Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO)
NMRA

Proactive Investors
Neumora Therapeutics stock surges as Amgen confirmed as major holder of the novel depression drug developer
NeutralNMRASeptember 27, 2023
Proactive InvestorsNeutral
Neumora Therapeutics stock surges as Amgen confirmed as major holder of the novel depression drug developer
NMRA

Market Watch
Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics
NeutralNMRASeptember 27, 2023
Market WatchNeutral
Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics
NMRA
About Neumora Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees63
CEODr. Joshua Pinto Ph.D.
IPO DateSep 15, 2023
HeadquartersWatertown, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul L. Berns | Executive Chairman | 1967 |
| Dr. Joshua Pinto Ph.D. | President, CEO & Director | 1985 |
| Dr. Daljit Singh Aurora Pharm.D. | Chief Operationg & Development officer | 1968 |
| Mr. Michael Lee Milligan | CFO & Principal Accounting Officer | 1973 |
| Dr. Nicholas Brandon Ph.D. | Chief Scientific Officer | 1975 |
| Mr. Pablo Gersberg | Chief Information Officer | — |
| Mr. Jason G. Duncan J.D. | Chief Legal & Administrative Officer | 1974 |
| Helen Rubinstein | Head of Investor Relations | — |
| Ms. Amy Sullivan | Chief Human Resources Officer | — |
| Mr. David Phillips M.B.A. | Senior Vice President & Head of Quality | — |
Fundamentals
Valuation
Market cap$127.32M
Price-to-sales ratioN/A
Price-to-book value2.97
Price-earnings ratio-0.60
Return on Equity-182.00%
Return on SalesN/A
Return on Assets-119.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.23
Income Statement
Average volume1,327,689
EBITDA$-216.13M
1 year high (52w)$3.65
1 year low (52w)$0.68
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
1 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$5.00
Est return
614.29%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -13.2 | -0.8 | +13.5 | +38.3 | ||||||||
| 2024 | -11.8 | +15.6 | -23.8 | -34.8 | +8.8 | +1.3 | +29.4 | -8.9 | +23.0 | -15.2 | -11.0 | +8.2 |
| 2025 | -2.0 | -16.1 | -29.1 | -14.3 | -6.5 | -2.7 | +145.0 | +10.9 | +4.6 | +69.7 | -25.6 | -26.0 |
| 2026 | +19.9 | +76.3 | -39.1 | +18.2 | -24.2 | -6.6 | -0.6 | -18.9 | -48.9 |



